These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34557821)

  • 41. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
    Poljak M; Oštrbenk A
    Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Age-specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross-sectional study.
    Bao H; Ma L; Zhao Y; Song B; Di J; Wang L; Gao Y; Ren W; Wang S; Wu J; Wang HJ
    Cancer Commun (Lond); 2022 Mar; 42(3):191-204. PubMed ID: 35142100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cervical cancer screening. Organised screening to avoid unnecessary conisation.
    Prescrire Int; 2010 Aug; 19(108):172-7, 179. PubMed ID: 20939454
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
    Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
    Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.
    Arbyn M; Simon M; de Sanjosé S; Clarke MA; Poljak M; Rezhake R; Berkhof J; Nyaga V; Gultekin M; Canfell K; Wentzensen N
    Lancet Oncol; 2022 Jul; 23(7):950-960. PubMed ID: 35709810
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay.
    Benoy I; Xu L; Vanden Broeck D; Poljak M; Oštrbenk Valenčak A; Arbyn M; Bogers J
    J Clin Virol; 2019 Nov; 120():57-62. PubMed ID: 31569008
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial.
    Denny L; Kuhn L; Hu CC; Tsai WY; Wright TC
    J Natl Cancer Inst; 2010 Oct; 102(20):1557-67. PubMed ID: 20884893
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Participation in the nationwide cervical cancer screening programme in Denmark during the COVID-19 pandemic: An observational study.
    Olesen TB; Jensen H; Møller H; Jensen JW; Waldstrøm M; Andersen B
    Elife; 2023 Jan; 12():. PubMed ID: 36661213
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Performance of HPV testing, Pap smear and VIA in women attending cervical cancer screening in Kilimanjaro region, Northern Tanzania: a cross-sectional study nested in a cohort.
    Mremi A; Mchome B; Mlay J; Schledermann D; Blaakær J; Rasch V
    BMJ Open; 2022 Oct; 12(10):e064321. PubMed ID: 36316070
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program.
    Wentzensen N; Clarke MA; Bremer R; Poitras N; Tokugawa D; Goldhoff PE; Castle PE; Schiffman M; Kingery JD; Grewal KK; Locke A; Kinney W; Lorey TS
    JAMA Intern Med; 2019 Jul; 179(7):881-888. PubMed ID: 31081870
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.
    Hariri S; Bennett NM; Niccolai LM; Schafer S; Park IU; Bloch KC; Unger ER; Whitney E; Julian P; Scahill MW; Abdullah N; Levine D; Johnson ML; Steinau M; Markowitz LE;
    Vaccine; 2015 Mar; 33(13):1608-13. PubMed ID: 25681664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical relevance of the borderline results of the Hybrid Capture 2 High-Risk HPV DNA assay with cervical samples collected in Specimen Transport Medium.
    Varl J; Ivanus U; Marinsek ZP; Jerman T; Valencak AO; Poljak M; Prevodnik VK
    Radiol Oncol; 2019 Sep; 53(3):316-322. PubMed ID: 31553700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protecting the underscreened women in developed countries: the value of HPV test.
    Ibáñez R; Autonell J; Sardà M; Crespo N; Pique P; Pascual A; Martí C; Fibla M; Gutiérrez C; Lloveras B; Moreno-Crespi J; Torrent A; Baixeras N; Alejo M; Bosch FX; de Sanjosé S
    BMC Cancer; 2014 Aug; 14():574. PubMed ID: 25102758
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
    Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
    BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Sequential Rounds of Cervical Cancer Screening on Management of HPV-positive Women: A 15-year Population-based Cohort Study from China.
    Xu XQ; Rezhake R; Hu SY; Chen F; Zhang X; Pan QJ; Zhang WH; Ma JF; Qiao YL; Zhao FH; Cruickshank M
    Cancer Prev Res (Phila); 2021 Mar; 14(3):363-372. PubMed ID: 33303694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Designing low-cost, accurate cervical screening strategies that take into account COVID-19: a role for self-sampled HPV typing2.
    Ajenifuja KO; Belinson J; Goldstein A; Desai KT; de Sanjose S; Schiffman M
    Infect Agent Cancer; 2020; 15():61. PubMed ID: 33072179
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
    Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
    BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme.
    Nygård M; Røysland K; Campbell S; Dillner J
    BMJ Open; 2014 Jan; 4(1):e003460. PubMed ID: 24401720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.